CORE 3 - CLINICAL TRANSLATIONAL RESEARCH CORE (CTRC): ABSTRACT The objective of the Clinical Translational Research Core (CTRC) is to facilitate high-quality clinical translational research specifically applicable to the understanding, prevention and treatment of diabetes, its complications, and related metabolic disorders. Research supported by the CTRC will leverage use of core facilities and faculty with expertise in a broad range in clinical research methods, from proof of concept and physiology, to clinical trials or comparative effectiveness studies to support the more than 35 Principal Investigators doing clinical research at Joslin. The CTRC will support the bi-directional journey of discovery from molecule, to model, to man, and back, while serving as the bridge between clinical observation, bench, and human investigation in adult and pediatric patients. Joslin has invested in new facilities for the Clinical Research Center which will serve as the infrastructure for the new DRC core. These facilities include exercise training and testing capacities, infusion and procedure rooms for adult and pediatric volunteers, and laboratory processing and biobanking facilities for valuable human specimens. We have well-trained nursing and technical staff to perform gold standard euglycemic, hyperglycemic, and hypoglycemic clamps at physiologic or pharmacologic insulin concentrations; intravenous and oral glucose and mixed meal tolerance tests; and other metabolic testing to assess insulin secretion, insulin action, and other metabolic processes for patient centered research specific to diabetes.
Specific aims of the new core are to 1) enable proof-of-concept and first-in-man ?T1? translational research programs with specific focus on Prediction, Prevention, and Interdiction of type 1 (T1DM) and type 2 diabetes (T2DM) and related complications; 2) facilitate design, implementation, and evaluation of investigator-initiated clinical trials and observational studies for translation to patients in ?T2-T3? research programs focused on improving and optimizing treatments of T1DM or T2DM and related complications; and 3) generate and maintain a registry of and a diabetes-specific biorepository of samples from our unique Joslin cohorts of patients with unusual phenotypes that have been extensively characterized. To achieve these aims the CTRC will provide an integrated and efficient core to support collaborative, multidisciplinary diabetes clinical research with services that include: a) consultation services, training, and mentoring of Investigators and fellows in methods and regulatory processes specific to human investigation; b) expert professional and technical help in the development and execution of protocols specific to diabetes and the complex assessments of glycemia, insulin secretion, insulin action, and exercise; c) support for biospecimen samples and data management; and d) guidance for analysis and interpretation of data and findings. Training will be an important component of the core supporting fellows and both new and established investigators. Together, these new initiatives will facilitate the translation of seminal observations and discoveries (which may begin at bench or bedside) into new diabetes cures or therapeutic opportunities.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Joslin Diabetes Center
United States
Zip Code
Lynes, Matthew D; Shamsi, Farnaz; Sustarsic, Elahu Gosney et al. (2018) Cold-Activated Lipid Dynamics in Adipose Tissue Highlights a Role for Cardiolipin in Thermogenic Metabolism. Cell Rep 24:781-790
Schuster, Cornelia; Jonas, Franziska; Zhao, Fangzhu et al. (2018) Peripherally induced regulatory T cells contribute to the control of autoimmune diabetes in the NOD mouse model. Eur J Immunol 48:1211-1216
Laguna Sanz, Alejandro J; Mulla, Christopher M; Fowler, Kristen M et al. (2018) Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia. Diabetes Technol Ther 20:127-139
Bhattacharya, Asmita; Sun, Shengyi; Wang, Heting et al. (2018) Hepatic Sel1L-Hrd1 ER-associated degradation (ERAD) manages FGF21 levels and systemic metabolism via CREBH. EMBO J 37:
Rabiee, Atefeh; Krüger, Marcus; Ardenkjær-Larsen, Jacob et al. (2018) Distinct signalling properties of insulin receptor substrate (IRS)-1 and IRS-2 in mediating insulin/IGF-1 action. Cell Signal 47:1-15
Cai, Weikang; Xue, Chang; Sakaguchi, Masaji et al. (2018) Insulin regulates astrocyte gliotransmission and modulates behavior. J Clin Invest 128:2914-2926
Nowak, Natalia; Skupien, Jan; Smiles, Adam M et al. (2018) Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int 93:1198-1206
Aguayo-Mazzucato, Cristina; Lee Jr, Terence B; Matzko, Michelle et al. (2018) T3 Induces Both Markers of Maturation and Aging in Pancreatic ?-Cells. Diabetes 67:1322-1331
Bartelt, Alexander; Widenmaier, Scott B; Schlein, Christian et al. (2018) Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat Med 24:292-303
Fujisaka, Shiho; Avila-Pacheco, Julian; Soto, Marion et al. (2018) Diet, Genetics, and the Gut Microbiome Drive Dynamic Changes in Plasma Metabolites. Cell Rep 22:3072-3086

Showing the most recent 10 out of 1120 publications